Fundz

Fundz Deep Dive

Everything you need to win Mabylon AG — in one platform.

Who to reach, what to say, and why now on Mabylon AG — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.

Get the full Deep Dive on Mabylon AG — free.

One free Deep Dive, emailed to you. No spam; unsubscribe anytime.

Ready now? Choose your plan · Request a demo · Sign in

Engage writes the reply
Grounded in signals no one else has — tuned to their persona.
Signals no one else has
UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.
Verified contact + click-to-call
The decision-maker’s email and mobile — dial in-browser.

Mabylon AG Receives More Than CHF 1.3 Million Research Grants for ALS and Inflammasome Programs

Sep 24, 2024•over 1 year ago

Contract Type

partnership

SchlierenBiotechnology

Description

Mabylon AG has received three grants totaling more than CHF 1.3 million from Innosuisse Swiss Innovation Agency, Target ALS, and the ALS Association. The funding is dedicated to advancing the development of human-derived TDP-43 intrabodies for amyotrophic lateral sclerosis (ALS) and the further development of Mabylon's MY012 program for the treatment of inflammatory bowel disease (IBD) with superior safety and efficacy.

Company Information

Company

Mabylon AG

Location

Schlieren, Zurich, Switzerland

About

Mabylon AG, a private Swiss biotech company, is leading innovation in antibody-based treatments for severe allergies, inflammation, and neurological disorders. Our B-cell screening platform rapidly identifies natural human antibodies with high specificity and therapeutic potential. MY006, our first-in-class multispecific antibody therapeutic for peanut allergy, is tackling the growing food allergy market.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence
Strategic

ML-powered predictions for Mabylon AG's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.